PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2008New England Journal of Medicine1,843 citationsOpen Access

HLA-B*5701 Screening for Hypersensitivity to Abacavir

View Full Paper
SMS. MallalEPElizabeth J. PhillipsGCGiampiero Carosi

Key Points

  • This study aims to evaluate the impact of HLA-B*5701 screening on the risk of hypersensitivity to abacavir.
  • HLA-B*5701 screening conducted in a predominantly white population
  • Pharmacogenetic testing applied to assess risk of hypersensitivity
  • ClinicalTrials.gov number, NCT00340080 provided for study registry.
  • 94% of patients tested do not carry the HLA-B*5701 allele and are at low risk for abacavir hypersensitivity
  • Pharmacogenetic testing effectively prevents the toxic effect of abacavir

Abstract

HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mallal et al. (2008) studied this question.

synapsesocial.com/papers/69de6b6f726bee048db0c06bhttps://doi.org/10.1056/nejmoa0706135
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients2008 · 432 citations
  2. 2Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population2007 · 147 citations
  3. 3External Quality Assessment of HLA-B*5701 Reporting: An International Multicentre Survey2007 · 43 citations
  4. 4PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events2007 · 53 citations
  5. 5A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome2006 · 50 citations